DDInter35 DDInter782
A benzimidazole broad-spectrum anthelmintic structurally related to mebendazole that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38)
In April 2018, the U.S. Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for patients experiencing chemotherapy-induced nausea and vomiting . Fosnetupitant is the pro-drug form of netupitant [FDA label]. Generally, 25% to 30% of patients with a diagnosis of cancer receive chemotherapy as a treatment modality and 70% to 80% of these patients undergoing chemotherapy treatment may experience nausea and vomiting as major side effects. Considered one of the most distressing side effects of chemotherapy, nausea and vomiting has an immense impact on the quality of life of patients receiving certain antineoplastic therapies .
Albendazole {u} (Compound) resembles {v} (Compound) Mebendazole
Albendazole {u} (Compound) binds {v} (Gene) ABCB1
Albendazole {u} (Compound) upregulates {v} (Gene) KIF14
Albendazole {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 1A Inducers
Albendazole {u} (Compound) downregulates {v} (Gene) GNPDA1
Albendazole {u} (Compound) causes {v} (Side Effect) Acute hepatic failure
Albendazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cimetidine
Albendazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dexamethasone
Albendazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Carbamazepine
Albendazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nevirapine
Albendazole (Compound) resembles Mebendazole (Compound)
Albendazole (Compound) binds ABCB1 (Gene)
Albendazole (Compound) upregulates KIF14 (Gene)
Albendazole (Compound) is included by Cytochrome P450 1A Inducers (Pharmacologic Class)
Albendazole (Compound) downregulates GNPDA1 (Gene)
Albendazole (Compound) causes Acute hepatic failure (Side Effect)
Albendazole may cause a minor interaction that can limit clinical effects when taken with Cimetidine
Albendazole may cause a minor interaction that can limit clinical effects when taken with Dexamethasone
Albendazole may cause a moderate interaction that could exacerbate diseases when taken with Carbamazepine
Albendazole may cause a moderate interaction that could exacerbate diseases when taken with Nevirapine